buyWeak

Orbimed Advisors LLC bought $998k of TRAW

owner at Onconova Therapeutics, Inc.. 597,729 shares at an average of $1.67, traded Apr 16, 2026, filed Apr 28, 2026.

Conviction score

Value

$998k

597,729 shares

Holdings after

1,203,250

+99% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
10% owner
+12
Trade size
$998k at market
+25
Relative to holdings
Holdings up 99%
+10
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Median 6-month excess return -26% over 4 past buys
-5
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

TRAWOct 12, 2026 · close 0.42

Since filing Apr 28, 2026: -65.6%SPY +9.9% · excess -75.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000947871-26-000481, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Apr 16, 2026	POpen-market purchase Common Stockindirect: See Footnote	+597,729	$1.67	$998k	1,203,250	Apr 28, 2026
Apr 16, 2026	POpen-market purchase Series A Warrants (right to buy)derivativeindirect: See Footnote	+597,729	-	-	597,729	Apr 28, 2026
Apr 16, 2026	POpen-market purchase Series B Warrants (right to buy)derivativeindirect: See Footnote	+597,729	-	-	597,729	Apr 28, 2026
Apr 16, 2026	POpen-market purchase Series C Warrants (right to buy)derivativeindirect: See Footnote	+1,793,187	-	-	1,793,187	Apr 28, 2026

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.